

Obstructive sleep apnoea

Navigating the system

CLAIRE M. ELLENDER BSc, MB BS, FRACP

CERYS JONES BSc, MB BS, FRACGP, DRANZCOG, DCH

CRAIG HUKINS BSc, MB BS, FRACP

Obstructive sleep apnoea (OSA) is becoming increasingly prevalent in our communities. GPs are well placed to recognise, investigate and manage many patients with uncomplicated OSA. Navigating the system to help patients access diagnostic sleep studies and appropriate treatment can be difficult. This article aims to demystify the system and help facilitate timely treatment.

KEY POINTS

- Obstructive sleep apnoea (OSA) is a common chronic disease and is increasing in prevalence.
- A focused history is important to evaluate for the likelihood of OSA and to identify patients at risk of the consequences of untreated OSA.
- A sleep study is needed to confirm the diagnosis and evaluate the severity of disease.
- Continuous positive airway pressure (CPAP) therapy is the gold standard for many symptomatic patients with moderate to severe OSA.
- Other treatment options are available for less severe disease or for those with difficulties in using CPAP.



All GPs will have seen patients dragged in by their bed partner with fatigue, loud snoring and excessive daytime sleepiness and suspected obstructive sleep apnoea (OSA) to be the likely diagnosis. OSA is a sleep disorder characterised by obstruction or collapse of the upper airway during sleep, resulting in oxygen desaturation and sleep fragmentation. It is the most common cause of excessive daytime sleepiness, unrefreshing sleep and snoring, and a cause of reduced workplace productivity.

OSA is increasing in prevalence in Australia due to increasing obesity.¹ It is a very treatable disease, often with continuous positive airway pressure (CPAP) therapy. However, navigating the system from symptoms to treatment requires a customised approach to match the patient with the correct testing modality and treatment.

With the increase in prevalence of OSA, management of OSA is increasingly becoming the domain of primary care. This article aims to demystify the system and help facilitate timely treatment, to help our patients feel less sleepy, more productive and have lower motor vehicle accident risk. Patients without significant comorbidities and a history consistent with OSA are suitable for GP-referred sleep studies and can be initiated on therapy in the community with follow up at the primary care level. This article will cover the specific comorbidities and history to look for to stratify patients into those who can be managed in primary care and those who require in-laboratory studies and sleep physician review.

MedicineToday 2021; 22(12): 29-35

Dr Ellender is a Respiratory and Sleep Physician at the Princess Alexandra Hospital, Metro South Hospital and Health Service, Brisbane; and Senior Lecturer at the Faculty of Medicine, Princess Alexandra Southside Clinical Unit, University of Queensland, Brisbane. Dr Jones is a General Practitioner at Eastbound Medical Clinic, Bentleigh East, Melbourne, Vic. Dr Hukins is a Respiratory and Sleep Physician at the Princess Alexandra Hospital, Metro South Hospital and Health Service, Brisbane; and Associate Professor at the Faculty of Medicine, Princess Alexandra Southside Clinical Unit, University of Queensland, Brisbane, Qld.




Figure. Obstructive sleep apnoea pathophysiology and link to symptoms.

1. KEY FEATURES OF OSA

- Habitual snoring
- Fatigue
- Excessive daytime sleepiness
- Witnessed apnoeas
- Disturbed or unrefreshing sleep
- Waking with choking or gasping
- Driving inattention
- Sleepiness-related accidents
- Hypertension despite more than two hypertension medications

Abbreviation: OSA = obstructive sleep apnoea.

Presenting features and their assessment

The key presenting features of OSA are listed in Box 1. A history of excessive daytime sleepiness and nocturnal choking or gasping is the most predictive for a diagnosis of OSA. Although some patients will present with nocturnal symptoms of snoring, a history of nonrestorative sleep, morning headaches and need for an afternoon nap can also point to this diagnosis.

The most widely validated self-report tool to quantify excessive daytime sleepiness is the Epworth Sleepiness Scale.¹¹ The scale is a summation of eight items, with a score above nine considered higher than normal daytime sleepiness and greater than 16 suggestive of severe excessive daytime sleepiness. The STOP-BANG, OSA-50 and Berlin questionnaires are validated screening tools for sleep apnoea.¹²⁻¹⁴ Significant results with these tools are a score of 3 or higher for the STOP-BANG questionnaire, a score of 5 or higher for the OSA-50 questionnaire and a ‘high risk’ result for the Berlin questionnaire.

An approach to the primary care investigation and treatment of a patient with OSA is shown in the Flowchart.

Investigating patients suspected to have OSA

In a patient with symptoms suggestive of OSA, a sleep study (polysomnogram) is needed to make a formal diagnosis. A

Consequences of untreated OSA

The pathophysiology of OSA is shown in the Figure. Untreated severe OSA is associated with a fourfold increase in all-cause mortality and increased cardiovascular disease, such as ischaemic stroke, myocardial infarction, hypertension and arrhythmia.²

Severe OSA is also associated with a sevenfold increased risk for multiple vehicle crashes in a five-year period, independent of age and driving time.^{3,4} It is essential to ask about driving safety when taking a sleep history – falling asleep at the traffic lights, near misses or inattention due to sleepiness and previous sleepiness-related accidents are predictors of motor-vehicle accident risk.

Additionally, severe OSA is associated with a 25% increased relative risk for developing cancer, controlling for confounders.⁵

Epidemiology


Across all populations, at least 14% of men and 5% of women will have some of sort of OSA.^{6,7} OSA has been increasing in prevalence in recent years.⁸

Data from the Bettering the Evaluation and Care of Health (BEACH) program has shown that sleep disturbance is within the top 30 reasons for attendance in general practice.⁹

Risk factors

The common risk factors for OSA are age greater than 65 years, obesity, male sex and anatomical features such as retrognathia.³ Obese adults (body mass index [BMI] greater than 30kg/m²) have as high as a 45% risk of OSA, compared with a 25% risk in those who are overweight (BMI 25 to 29.9kg/m²).¹⁰ There is a strong association between OSA and other chronic diseases such as heart failure and end-stage kidney disease.

SUGGESTED PRIMARY CARE INVESTIGATION AND TREATMENT OF PATIENTS WITH OSA



Abbreviations: AHI = apnoea-hypopnoea index; CPAP = continuous positive airway pressure; ESS = Epworth Sleepiness Scale; OSA = obstructive sleep apnoea; SpO2 = oxygen saturation.

* See Box 3 for relevant comorbidities.

† High risk features for motor vehicle crashes: excessive daytime sleepiness (ESS 16 to 24); sleepiness while driving; near-miss events; previous history of crashes caused by inattention or sleepiness.

‡ Mandibular advancement splint indicated for mild to moderate OSA with no significant oxygen desaturation and for patients intolerant of CPAP therapy.

§ Positional therapy indicated for mild to moderate OSA with AHI ≤15 events/hour in the lateral position.

¶ Surgery indicated for mild symptomatic OSA where reversible risk factors have been optimised, or for other patients with OSA who cannot tolerate other therapies.

2. CRITERIA FOR GP-REFERRED OSA DIAGNOSTIC SLEEP STUDY

Medicare subsidy criteria for referral of a patient by a GP for an overnight sleep study to confirm diagnosis of OSA:

- Epworth Sleepiness Scale score ≥ 8
- plus one of:
 - STOP-BANG Questionnaire score ≥ 3
 - OSA-50 Screening Questionnaire score ≥ 5
 - Berlin Questionnaire result ‘high risk’

Websites

Epworth Sleepiness Scale

<https://epworthsleepinessscale.com/about-the-ess/>

STOP-BANG Questionnaire

<http://www.stopbang.ca/osa/screening.php>

OSA-50 Screening Questionnaire

<https://thorax.bmj.com/content/thoraxjnl/66/3/213.full.pdf>

Berlin Questionnaire

<https://www.sleepapnea.org/wp-content/uploads/2017/02/berlin-questionnaire.pdf>

Abbreviation: OSA = obstructive sleep apnoea.

sleep study involves measurement of electroencephalography (EEG) to confirm sleep stage, as well as measurement of chest and abdominal wall movement, nasal airflow and pressure, in addition to oxygen saturation, ECG and leg movements. Using data from the sleep study, OSA is categorised as mild, moderate or severe disease, based on the number of obstructive events per hour, known as the apnoea-hypopnoea index (AHI). An AHI of five to 14 events per hour indicates mild OSA, an AHI of 15 to 29 indicates moderate OSA and an AHI of greater than 29 indicates severe OSA.⁶

A Medicare subsidy is available for GP referral of patients for overnight sleep studies to confirm the diagnosis of OSA, providing certain criteria are met (Box 2).

At-home sleep studies versus in-laboratory sleep studies

Most patients being investigated for OSA will be suitable for an unattended ‘type 2’

TABLE 1. IN-LABORATORY VERSUS HOME-BASED DIAGNOSTIC SLEEP STUDY SELECTION FOR OSA DIAGNOSIS

Feature	Type 1 (in-laboratory) sleep study	Type 2 (home-based) sleep study
Advantages		
Patient selection	<ul style="list-style-type: none"> • Patients with certain comorbidities, such as those with: <ul style="list-style-type: none"> – neuromuscular disease – morbid obesity – significant chronic obstructive pulmonary disease or heart failure – severe cognitive impairment or high falls risk (e.g. frail patients or with poor co-ordination) 	<ul style="list-style-type: none"> • Most symptomatic people without hypoventilation risk factors (Medicare rebate available)
Accuracy	<ul style="list-style-type: none"> • Signal failure extremely unlikely 	<ul style="list-style-type: none"> • Comparable accuracy in populations without significant comorbidity or complexity • Data signals may gradually degrade as the night wears on
Additional data	<ul style="list-style-type: none"> • Captures additional data accurately, such as: <ul style="list-style-type: none"> – body position – parasomnia – leg movements 	–
Additional interventions	<ul style="list-style-type: none"> • Can add additional interventions, such as: <ul style="list-style-type: none"> – oxygen – mandibular advancement splint • Could change to a treatment study if OSA severe 	–
Disadvantages		
	<ul style="list-style-type: none"> • Labour intensive • Limited access to Medicare funding • Limited laboratories across Australia 	<ul style="list-style-type: none"> • Risk of partner/pet artefact • Requires multiple trips to the testing clinic to obtain and return equipment • Does not monitor position or carbon dioxide level • Not able to commence therapy on the same night

Abbreviation: OSA = obstructive sleep apnoea.

Adapted from Douglas JA, et al. (2017) Guidelines for sleep studies in adults – a position statement of the Australasian Sleep Association.¹⁵

home-based sleep study (sometime also referred to as a ‘level 2 study’). Home-based studies can be used to confirm the diagnosis of OSA in patients with a highly suspicious history. However, because of the reduced data-set compared with laboratory testing, home sleep studies are not usually appropriate for investigating

other sleep disorders, such as parasomnia, narcolepsy, nocturnal seizures or suspected hypoventilation disorders.

Attended in-laboratory diagnostic sleep studies (‘type 1 studies’) are needed where contraindications exist or for a second opinion, and require a sleep medicine practitioner or respiratory physician

3. OSA PATIENTS TO REFER FOR SLEEP MEDICINE SPECIALIST INPUT¹⁷

- Patients with severe comorbidities such as heart failure, risk of hypoventilation (COPD, neuromuscular disease, BMI >35 kg/m²)
- Patients with a commercial driver's license – including bus, train, truck, ride-share and taxi drivers, couriers and crane and forklift operators
- Patients who are high-risk for motor vehicle crashes:
 - moderate to severe excessive daytime sleepiness (ESS 16 to 24)
 - sleepiness while driving or near-miss events (driving outside the lines or falling asleep at traffic lights)
 - previous history of motor vehicle crashes caused by inattention or sleepiness
- Patients who require access to government programs for equipment access
- Patients with persistent symptoms (ESS ≥10) despite CPAP initiation

Abbreviations: BMI = body mass index; CPAP = continuous positive airway pressure; COPD = chronic obstructive pulmonary disease; ESS = Epworth Sleepiness Scale; OSA = obstructive sleep apnoea.

referral to be eligible for Medicare funding. Type 3 and 4 studies measure oxygen saturation and nasal airflow, without electroencephalography; these are not widely available, or Medicare subsidised. Table 1 summarises the indications, advantages and disadvantages of in-laboratory and home sleep studies.¹⁵

As shown in Box 2, in an adult with a suggestive history, who meets the Epworth Sleepiness Scale and other questionnaire criteria, GPs are the key healthcare providers for referring patients to get a Medicare subsidised 'Type 2' sleep study, providing there are no features that require a sleep physician review (Box 3). In-laboratory studies require a sleep physician review for the study to be Medicare subsidised. Box 3 summarises the patient groups who would benefit from input from a sleep medicine specialist.¹⁶

TABLE 2. GUIDE FOR INTERPRETING THE SLEEP STUDY REPORT IN PATIENTS WITH SUSPECTED OSA

Parameter	Explanation
Total sleep time	>3 hours (180 minutes), preferably longer, to ensure all sleep stages are seen
REM sleep	Confirm REM sleep was seen (OSA is usually worse in REM)
Body position	Confirm supine sleep seen (OSA is usually worse in supine position)
Respiratory disturbance index or apnoea-hypopnoea index	Determines the severity of OSA: <ul style="list-style-type: none"> • mild OSA: AHI 5 to 14 events/hour • moderate OSA: AHI 15 to 29 events/hour • severe OSA: AHI ≥30 events/hour
Oxygen saturation <85%	Oxygen saturation <85% for more than 50% of the study indicates the need for sleep specialist input
Oxygen saturation <90%	Oxygen saturation <90% for >10% of the night is associated with an increased cardiovascular risk, particularly hypertension

Abbreviations: AHI = apnoea-hypopnoea index; OSA = obstructive sleep apnoea; REM = rapid eye movement.

Key results from a sleep study

The key parameters to review in a sleep study report are summarised in Table 2. Building a relationship with local sleep study testing facilities is helpful for consistent results. To check which laboratories in your local area are accredited, see the National Association of Testing Authorities, Australia (NATA) website (www.nata.com.au/accredited-facility) and search by state using the keyword 'sleep'.

Treatment options for OSA

Unfortunately, OSA is a chronic disease that rarely resolves spontaneously. OSA treatment options include positive airway pressure (PAP), a mandibular advancement splint, surgery, positional therapy and weight loss.

CPAP

The gold standard treatment for OSA is CPAP. The CPAP machine is a small bedside pump connected to the patient's upper airway via a mask attached to their face, splinting the airway open. Auto-titrating CPAP (APAP) is a form of CPAP delivered by a device that contains sensors to increase and decrease the pressure in order to maintain a patent airway. Most patients do not require auto-titrating

CPAP machines; for more information see our follow-up article about CPAP therapy in a future issue of *Medicine Today*.

CPAP is indicated in symptomatic moderate to severe OSA, or mild OSA with an oxygen saturation (SpO₂) less than 90% for greater than 10% of the night.

CPAP is a highly effective treatment for OSA. There is strong evidence that CPAP therapy for people with OSA improves the AHI and daytime sleepiness, reduces motor-vehicle accident risk, and increases quality of life.¹⁷ The number needed to treat to achieve a two-point reduction on the Epworth Sleepiness Scale is only four, with a cost to the healthcare system of only about \$550 per person per year.^{11,18} Another advantage of CPAP therapy is that the CPAP machine can be rented to test for symptom improvement before purchase.

Disadvantages of CPAP therapy include side effects and the cost of the device and mask replacement. Side effects such as nasal congestion and dry mouth are common, and adherence to CPAP therapy of greater than four hours per night is required to obtain ongoing benefits.

Mandibular advancement splints

Mandibular advancement splints advance the lower jaw while the wearer sleeps. They

TABLE 3. IMMEDIATE AUTO-TITRATING CPAP (APAP) TREATMENT VERSUS IN-LABORATORY CPAP TITRATION STUDY IN OSA PATIENTS

	Option 1: Straight to auto-titrating CPAP	Option 2: In-laboratory CPAP titration study
Indications	<ul style="list-style-type: none"> • Patients with: <ul style="list-style-type: none"> – moderate or severe OSA – ESS score >9 – no significant comorbidities 	<ul style="list-style-type: none"> • Patients with: <ul style="list-style-type: none"> – significant comorbidities, or – the need for specialist scientific staff education
Advantages	<ul style="list-style-type: none"> • Fast access to effective therapy 	<ul style="list-style-type: none"> • Ability to titrate specifically for hypoventilation and central sleep apnoea • Independent education • Early troubleshooting for side effects
Disadvantages	<ul style="list-style-type: none"> • Education is dependent on commercial enterprise, with variable quality • Potential commercial conflict of interest 	<ul style="list-style-type: none"> • Costly • Limited Medicare-rebated access • Delays to access due to limited availability

Abbreviations: CPAP = continuous positive airway pressure; ESS = Epworth Sleepiness Scale; OSA = obstructive sleep apnoea.

are custom-made by a specialist dentist. The Australasian Sleep Association list of accredited sleep dental services can be found online in the Sleep Services Directory by selecting OSA – Dental Treatment and your location (www.sleep.org.au/public/resources/sleep-directory).

Mandibular advancement splints are indicated in mild to moderate OSA in the absence of significant oxygen desaturation and in patients who are intolerant of CPAP therapy.¹⁹

The advantages of mandibular advancement splints are that they are more portable than CPAP machines and they are associated with fewer nasal side effects than CPAP therapy. Their disadvantages include their cost, the potential long-term changes to the wearer’s bite and the requirement for adequate dentition. Mandibular advancement splints generally cost between \$1200 and \$2500 and full payment before use is usually required.

Surgery

Surgery as a treatment for OSA remains largely a last resort, and is only indicated in patients with mild symptomatic OSA

where reversible risk factors (e.g. obesity) have been optimised, or for other OSA patients who cannot tolerate alternative therapies, following a sleep specialist opinion.¹⁶ The procedure involves debulking of the uvulae, palate and tongue with radiofrequency tissue ablation (known as a modified uvulopalatopharyngoplasty and coblation channelling of the tongue).

The advantage of surgery is that there is no ongoing requirement for device use; disadvantages include the risks of surgery and the limited longevity of efficacy as people age and gain weight.

Positional therapy

Positional therapy can be used for sleep apnoea where upper airway obstruction is present only in the supine position. Several forms of positional therapy are available, including vibro-tactile electronic devices, tennis balls sewn into a nightshirt and pillows with straps to prevent supine sleep. These are available for purchase through local CPAP retailers.

Positional therapy is indicated in mild to moderate OSA where there are

infrequent events in the lateral position (e.g. lateral AHI less than 15 events per hour).

The advantage of positional therapy is that it has fewer side effects than other treatments; a disadvantage is that long-term adherence is poor.

Weight loss

Weight loss of more than 10% body weight can improve the severity of OSA; however, even surgical weight loss has been shown to result in persistent OSA in most patients.²⁰ Thus, weight loss in isolation is not likely to be sufficient treatment for patients with moderate or severe OSA.

PAP treatment

Accessing CPAP treatment

Following confirmation of the diagnosis of OSA, some patients can commence APAP treatment immediately and others will require in-laboratory CPAP titration (Table 3). This can be done by GPs in primary care, via local CPAP retailers and without a sleep physician consultation if the patient is able to self-fund therapy. See Table 3 for a guide to which patients are suitable for auto-titrating CPAP and which patients require in-laboratory CPAP titration studies.

Patients are generally encouraged to rent an APAP machine for at least three nights and then rent a fixed pressure CPAP machine for two months prior to purchase of a CPAP machine to ensure tolerability. In most capital cities, rental of an APAP or CPAP machine costs about \$100 to \$200 each month. Masks cost about \$120 to \$300 and usually require replacement of head straps and silicon seals every 12 months.

After renting an APAP device, patients can either self-fund a CPAP machine, with settings titrated from the APAP findings, or can be referred to a local public sleep disorders unit to obtain a government-funded machine.

CPAP machines range in cost from around \$750 to \$2000, depending on the

4. STATE AND TERRITORY GOVERNMENT-FUNDED CPAP PROGRAMS AROUND AUSTRALIA²¹

Australian Capital Territory

- Local hospitals funded for CPAP through the territory-wide Domiciliary Oxygen and Respiratory Support Scheme: <https://www.health.act.gov.au/services-and-programs/rehabilitation/oxygen-and-equipment-services>

New South Wales

- State-wide program administered through ENABLE NSW via local hospitals: <https://www.enable.health.nsw.gov.au/prescribers/forms/hrp>

Northern Territory

- Difficult – no public hospital sleep laboratories
- Funding at the Royal Darwin Hospital for patients with proof of Northern Territory residence, severe OSA or AHI 5 to 30 with medical comorbidities following physician review

Queensland

- State-wide program through major teaching hospitals: <https://www.health.qld.gov.au/clinical-practice/referrals/statewide-specialist-services/sleep-disorders-program>

South Australia

- No state-based program – funding varies between local health networks

Tasmania

- State-wide program, but limitations on machine numbers – accessible through local hospitals

Victoria

- Variable across public hospitals
 - For those with respiratory failure, the Victoria Respiratory Support Service provides equipment and disposables through the Austin Hospital, Melbourne: <https://www.austin.org.au/victorian-respiratory-support-service>

Western Australia

- Sir Charles Gairdner Hospital and Fiona Stanley Hospitals have programs for those with a Healthcare Card
 - Sir Charles Gairdner Hospital – Pulmonary Physiology and Sleep Medicine: health.wa.gov.au
 - Respiratory Medicine: fsh.health.wa.gov.au

Abbreviations: AHI = apnoea hypopnoea index; CPAP = continuous positive airway pressure; OSA = obstructive sleep apnoea.

a rental period on CPAP to confirm adherence to treatment. Patients have to purchase their own masks.

Conclusion

OSA is a chronic disease with increasing prevalence in the community and can be effectively treated at relatively low cost. Its management is becoming the domain of primary care because of its increased prevalence. Navigating the system to initiate effective treatment for patients starts with a thorough history, recognition of indications for specialist referral, and knowledge of local services. High quality local sleep studies can expedite investigation and can be arranged by GPs where there are no red flags for specialist care. The conducting of a CPAP review appointment will be covered in our article on CPAP therapy in a future issue of *Medicine Today*. **MT**

References

A list of references is included in the online version of this article (www.medicinetoday.com.au).

COMPETING INTERESTS: None.

store and the type of device purchased. As a rough guide, however, most patients self-funding the machine should set aside \$1500 in total for rental, mask and machine purchase. A machine will last eight to 15 years if cleaned regularly. Masks generally need replacing every three years if they are cleaned each morning. Funding is available in some states and territories for patients unable to self-fund CPAP equipment (Box 4).²¹

Rebates

Private health insurance 'extras' will often reimburse around \$500 of the initial cost of the equipment, depending on the policy; a supporting letter from a clinician may be required.

For those with financial hardship and no concession card, an application can be made to release superannuation for purchasing medical equipment.

Forms can be found on the Australian Tax Office website (www.ato.gov.au; search for 'Compassionate release of superannuation').

Most electricity providers will provide a rebate and priority for restoring power in the event of supply issues. Concession or pension cardholders are eligible for an additional annual subsidy to Centrelink payments if an Essential Medical Equipment Payment Services Australia form is completed.

Government CPAP programs

Despite the strong data in support of CPAP, devices are not accessible through Medicare or Federal funding. There are several state-based programs for accessing government-funded CPAP machines for people with pension or concession cards. These programs generally require a referral to a designated centre and

ONLINE CPD JOURNAL PROGRAM

What are the advantages of a type 1 diagnostic sleep study?



Review your knowledge of this topic and earn CPD points by taking part in *Medicine Today's* Online CPD Journal Program. **Log in to** www.medicinetoday.com.au/cpd

© NICOLEY/ISTOCKPHOTO.COM
MODEL USED FOR ILLUSTRATIVE PURPOSES ONLY

Obstructive sleep apnoea

Navigating the system

CLAIRE M. ELLENDER BSc, MB BS, FRACP; **CERYS JONES** BSc, MB BS, FRACGP, DRANZCOG, DCH
CRAIG HUKINS BSc, MB BS, FRACP

References

1. Deloitte Access Economics, for the Sleep Health Foundation. Cost effectiveness of continuous positive airway pressure for obstructive sleep apnoea. Canberra: Deloitte Access Economics; 2018.
2. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. *Sleep* 2008; 31: 1071-1078.
3. Young T, Peppard P, Gottlieb D. Epidemiology of obstructive sleep apnea – a population health perspective. *Am J Respir Crit Care Med* 2002; 165: 1217-1239.
4. Karimi M, Hedner J, Häbel H, Nerman O, Grote L. Sleep apnea related risk of motor vehicle accidents is reduced by continuous positive airway pressure: Swedish Traffic Accident Registry Data. *Sleep* 2015; 38: 341-349.
5. Kendzerska T, Povitz M, Leung RS, et al. Obstructive sleep apnea and incident cancer: a large retrospective multicenter clinical cohort study. *Cancer Epidemiol Biomarkers Prev* 2021; 30: 295-304.
6. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med* 2017; 13: 479-504.
7. Garvey JF, Pengo MF, Drakatos P, Kent BD. Epidemiological aspects of obstructive sleep apnea. *J Thorac Dis* 2015; 7: 920-929.
8. Peppard PE, Young T, Barnett JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol* 2013; 177: 1006-1014.
9. Britt H, Miller GC, Henderson J, et al. General practice activity in Australia 2015–16. General practice series no. 40. Sydney: Sydney University Press; 2016.
10. Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive sleep apnea: implications for treatment. *Chest* 2010; 137: 711-719.
11. Johns MW. Sleepiness in different situations measured by the Epworth Sleepiness Scale. *Sleep* 1994; 17: 703-710.
12. Chai-Coetzer CL, Antic NA, Rowland LS, et al. A simplified model of screening questionnaire and home monitoring for obstructive sleep apnoea in primary care. *Thorax* 2011; 66: 213-219.
13. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. *Anesthesiology* 2008; 108: 812-821.
14. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. *Ann Intern Med* 1999; 131: 485-491.
15. Douglas JA, Chai-Coetzer CL, McEvoy D, et al. Guidelines for sleep studies in adults – a position statement of the Australasian Sleep Association. *Sleep Med* 2017; 36 Suppl 1: S2-S22.
16. Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med* 2009; 5: 263-276.
17. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med* 2019; 15: 335-343.
18. Craig SE, Kohler M, Nicoll D, et al. Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. *Thorax* 2012; 67: 1090-1096.
19. Ramar K, Dort LC, Katz SG, et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. *J Clin Sleep Med* 2015; 11: 773-827.
20. Wong AM, Barnes HN, Joosten SA, et al. The effect of surgical weight loss on obstructive sleep apnoea: a systematic review and meta-analysis. *Sleep Med Rev* 2018; 42: 85-99.
21. Australasian Sleep Association. Public funding of CPAP in Australia. Inquiry into sleep health awareness in Australia. Submission 118 – supplementary submission 1. Canberra: Australian Parliament House; 2019.